Brightgene Bio-medical Technology Co. Ltd. Class ASSE: 688166

"BrightGene Bio-Medical Technology Co., Ltd."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

Sep 9, 2026 · Issued by Brightgene Bio-medical Technology Co. Ltd. Class A via Shanghai Stock Exchange

Filed with SSE · Sep 9, 2026

Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Company analysis

Earlier from Brightgene Bio-medical Technology Co. Ltd. Class A

"BrightGene Bio-Medical Technology Co., Ltd."Semi-annual Report for 2026Aug 31
"Brightgene Bio-Medical Technology Co., Ltd."Announcement on Voluntary Disclosure of the Phase I Clinical Trial Data of BGM1812 Injection for Weight Loss IndicationAug 7
"Brightgene Bio-Medical Technology Co., Ltd."Voluntary Disclosure Announcement on Acquisition of Drug Registration Certificate for Tiotropium Bromide Inhalation Spray by a Controlled SubsidiaryAug 1
"Brightgene Bio-Medical Technology Co., Ltd."Voluntary Disclosure Announcement on Acquisition of Drug Registration Certificate for Tiotropium Bromide and Olodaterol Inhalation Spray by a Controlled SubsidiaryJul 25

All Brightgene Bio-medical Technology Co. Ltd. Class A news releases